SARS Spike
- Known as:
- SARS Spike
- Catalog number:
- ANT-179
- Product Quantity:
- 100µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- SARS Spike
Related genes to: SARS Spike
- Gene:
- SARS NIH gene
- Name:
- seryl-tRNA synthetase
- Previous symbol:
- -
- Synonyms:
- SERS
- Chromosome:
- 1p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-06-09
- Date modifiied:
- 2014-11-18
- Gene:
- SARS2 NIH gene
- Name:
- seryl-tRNA synthetase 2, mitochondrial
- Previous symbol:
- SARSM
- Synonyms:
- FLJ20450, mtSerRS, SerRSmt, SARS, SERS, SYS
- Chromosome:
- 19q13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-10-09
- Date modifiied:
- 2016-11-09
Related products to: SARS Spike
62 kDa RNA-binding protein,Oryctolagus cuniculus,Rabbit,SARS,Serine--tRNA ligase,SerRS,SERS,Seryl-tRNA synthetase, cytoplasmic,Seryl-tRNA(Ser_Sec) synthetaseSARS coronavirus N Protein monoclonal antibody, clone 38j4SARS coronavirus N Protein monoclonal antibody, clone 8k5hA' SARS-CoV, Spike Antibody (OAMA02852)A' SARS-CoV, Spike Antibody (OAMA02863)A'SARS-CoV, M protein (NT) antibodyA'SARS-CoV, M protein (NT) antibody Polyclonal Antibodies Primary antibodiesA'SARS-CoV, M protein (NT) antibody Polyclonal Antibody Host: RabbitACE2 (SARS Receptor) Antibody (C-term)ACE2 (SARS Receptor) Antibody (C-term)ACE2 (SARS Receptor) Antibody (C-term) Blocking PeptideACE2 (SARS Receptor) Antibody (C-term) Blocking PeptideACE2 (SARS Receptor) Antibody (C-term) Purified Rabbit Polyclonal Antibody (Pab) Applications WB, IHC, EACE2 (SARS Receptor) Antibody (C-term) Purified Rabbit Polyclonal Antibody (Pab) Applications WB, IHC, EACE2 (SARS Receptor) Antibody (Center) Related articles to: SARS Spike
- COVID-19 has proven to have a wide range of symptoms in human patients, prompting investigation into relevant biomarkers and underlying biological mechanisms. In this study, we aimed to develop a robust quantitative N-glycoproteomics approach for complex plasma samples and to characterize the altered glycosylation profiles associated with COVID-19 severity. We analyzed plasma samples from 16 survivors and 15 non-survivors, collected at three distinct time points following hospital admission. Using data-dependent acquisition (DDA) mass spectrometry, combined with a spectral library and the "match-between-runs" strategy, we profiled 397 unique glycopeptides and 62 glycan species, derived from 50 proteins across 86 glycosylation sites. By assessing both cross-sectional differences and longitudinal changes, we identified several site-specific glycosylation alterations that may serve as potential markers of disease severity. The most notable site-specific change was in the complement C1q A-chain (C1QA) at Asn146, with non-survivors having less fucosylation at hospital admission. We also observed increased bisection of immunoglobulins in non-survivors (IgG3/4 Asn177 and IgM Asn146) and glycosylation pattern changes in acute-phase proteins. Longitudinally, the fucosylation levels of C1QA increased in the non-survivors, whereas they decreased in the survivors. These findings highlight the potential value of site-specific glycoproteomic profiling for improving the molecular understanding of COVID-19 severity. - Source: PubMed
Publication date: 2026/09/23
Yu XueDingess KellyPavasini RitaCampo GianlucaSavino SpadaroHeck Albert J RReiding Karli R - Artificial Neural Networks (ANNs) hold promise in predicting disease severity from viral protein sequences. To gain clinical insights, the models must adhere to two key factors: first, they need to be interpretable, as using black-box models within a healthcare setting poses risks, and second, they should integrate viral and clinical features to correct for biases within the data. We propose ClinIAN (Clinically Informed Attention Network), an inherently interpretable end-to-end learning model that effectively combines clinical and sequence parameters. We evaluate ClinIAN within the context of the challenging task of predicting the severity of SARS-CoV-2 infection, but it could be applied to other medical and biological contexts, with sequence and tabular features, such as bacterial infections or cancer research. - Source: PubMed
Publication date: 2026/09/09
König FlorianDitz Jonas CShamsara ElhamHedberg PontusFanti IuriNauclér PontusCarioti LucaWalker AndreasParczewski MiloszDrobniewski FrancisCeccherini-Silberstein FrancescaZazzi MaurizioJensen Björn-Erik OleSönnerborg AndersPfeifer Nico - Clinically relevant preclinical models are critical for understanding acute respiratory distress syndrome (ARDS) and developing novel therapeutics. Although SARS-CoV-2 pseudovirus-based models overcome biosafety challenges associated with live coronavirus, their ability to recapitulate key ARDS features and respond to established treatment remains unclear. We developed a vesicular stomatitis virus expressing the SARS-CoV-2 spike protein (VSV-CoV2-S) for safe use in BSL-2 facilities. We evaluated its ability to induce acute lung injury (ALI) and its responsiveness to dexamethasone. Intratracheal inoculation of K18-hACE2 transgenic mice induced severe ALI characterized by alveolar damage, pulmonary hemorrhage, vascular hyperpermeability, inflammatory cytokine production, and immune cell infiltration. All inoculated transgenic mice died by day 6. Inoculated wild-type mice remained healthy. Dexamethasone attenuated clinical and histopathological ALI evidence in transgenic mice. This study confirms the translational validity of a pseudovirus-based approach, providing a robust and accessible platform to assess ALI pathophysiology and evaluate candidate therapies. - Source: PubMed
Publication date: 2026/09/15
Karunamurthy PrarthnaTieu AlvinChwastek DamianFisk Zoe AChander NikeshJahandideh ForoughEngelberts DoreenJamieson TaylorPetryk JuliaHe XiaohongIlkow CarolinaPoutou JoannaLansdell CaseyStewart Duncan JLalu Manoj M - Autonomic nervous system (ANS) dysfunction is a central feature of long coronavirus disease syndrome, yet little is known about how it develops during and after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. - Source: PubMed
Publication date: 2026/06/06
Liu TingAshok DeepthiPekosz AndrewVillano JasonO'Rourke Brian - The study aimed to determine the antibody response associated with physical activity (PA) levels and participants' individual characteristics following coronavirus disease 2019 (COVID-19) vaccination. - Source: PubMed
Publication date: 2026/09/08
Voulgaridi IoannaDinas Petros CBogogiannidou ZacharoulaDadouli KaterinaLianos Athanasios GPapageorgiou NikolasGeorgiou DimitriosZigas NikolaosBouloumpasi EleniSyrakouli EvangeliaSyrakouli ArgyroSarrou StylianiTseroni MariaKalala FaniMouchtouri Varvara ASpeletas MatthaiosKoutedakis YiannisHadjichristodoulou Christos